Adaptimmune Therapeutics, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, unveiled plans to expand its research and development operation into a major new purpose-built facility at Milton Park, Oxfordshire. Construction of Adaptimmune’s 67,000 square foot Enterprise Zone building is already under way following a groundbreaking ceremony. The flagship facility will provide laboratory space with associated offices, meeting rooms and a café area to...